Covariance of metabolic and hemostatic risk indicators in men and women

Fibrinolysis and Proteolysis

Volumn 15, Issue 1, 2001, Pages 9-20

  Riese, H ^a   Vrijkotte, T G M ^b   Meijer, P ^a   Kluft, C ^a   De Geus, E J C ^b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGE; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; COVARIANCE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; METABOLISM; NURSE; ORAL CONTRACEPTION; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035158235     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2001.0099     Document Type: Article

References (49)

1. Després JP, LaMarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
2. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
3. Wu KK, Folsom AR, Heis G, Davis CE, Colan MG, Barnes R. Association of coagulation factors and inhibitors with carotid artery atherosclerosis. Early results of the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 1992; 2: 471-480.
4. Dawson S, Henney A. The status of PAI-1 as risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992; 95: 105-117.
5. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
6. Gordon DJ, Probsfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 9-15.
7. Lindahl B, Asplund K, Eliasson M, Evrin P-E. Insulin resistance syndrome and fibrinolytic activity: the Northern Sweden MONICA Study. Intern J Epidemiol 1996; 25: 291-299.
8. Vague P, Raccah D, Scelles V. Hypofibrinolysis and the insulin resistance syndrome. Int J Obes Relat Metab Disord 1995; 19: S11-15.
9. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236: 13-22.
10. Asplund-Carlson A, Hamsten A, Wiman B, Carlson, LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825.
11. Daae LN, Kierulf P, Landaas S, Urdal P. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest 1993; 53: 19-27.
12. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991; 14: 461-469.
13. Schnall PL, Landsbergis PA, Baker D. Job strain and cardiovascular disease. Annu Rev Public Health 1994; 15: 381-411.
14. Markowe HLJ, Marmot MG, Shipley MJ et al. Fibrinogen: a possible link between social class and coronary heart disease. Br Med J 1985; 291: 1312-1314.
15. Siegrist J, Peter R, Cremer P, Seidel D. Chronic workstress is associated with atherogenic lipids and elevated fibrinogen in middle-aged men. J Int Med 1997; 242: 149-156.
16. Ishizaki M, Tsuritani I, Noboriska Y, Yamada Y, Tabata M, Nakagawa H. Relationship between job stress and plasma fibrinolytic activity in male Japanese workers. Int Arch Occup Environ Health 1996; 68: 315-320.
17. Mooy JM, Grootenhuis PA, De Vries H et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
18. De Maat MPM, De Bart ACW, Hennis BC et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 1156-1162.
19. Markman P, Sandstroøm B, Jespersen J. The variability of and the association between measures of blood coagulation, fibrinolysis and blood lipids. Atheroscler 1992; 96: 235-244.
20. Tunstall-Pedoe H, Woodward M, Tavendale R, Brook RA, McCluskey MK. General Practice: Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. Br Med J 1997; 315: 722-729.
21. Räikkönen K, Keltikangas-Jarvinen L, Adlercreutz H, Hautanen A. Psychosocial stress and the insulin resistance syndrome. Metabolism 1996; 45: 1533-1538.
22. Weidner G, Boughal T, Connor SL, Pieper C, Mendell NR. Relationship of job strain to standard coronary risk factors and psychological characteristics in women and men of the Family Heart Study. Health Psychol 1997; 16: 239-247.
23. Juhan-Vague I, Alessi MC, Raccah D et al. Daytime fluctuations of plasminogen activator inhibitor 1 (PAI-1) in populations with high PAI-1 levels. Thromb Haemost 1992; 67: 76-82.
24. De Geus EJC, Kluft C, De Bart ACW, Van Doornen LJP. Effects of exercise training on plasminogen activator inhibitor activity. Med Sci Sports Exerc 1992; 24: 1210-1219.
25. Brindley DN, McCann BS, Niaura R, Stoney CM, Suarez EC. Stress and lipoprotein metabolism: modulators and mechanisms. Metabolism 1993; 42: 3-15.
26. Niaura R, Stoney CM, Herbert PN. Lipids in psychological research: the last decade. Biol Psychol 1992; 34: 1-43.
27. Toft I, Bønaa KH, Ingebretsen OC, Nordøy A, Birkeland KI, Jenssen T. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension. Arterioscler Thromb Vasc Biol 1997; 17: 553-559.
28. Siegert G, Bergman S, Jaross W. Influence on age, gender and lipoprotein metabolism parameter on the activity of the plasminogen activator inhibitor and the fibrinogen concentration. Fibrinolysis 1992; 6: 47-51.
29. Van Kesteren PJ, Kooistra T, Lansink M et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998; 79: 1029-1033.
30. Jöreskog KG, Sörbom D. Lisrel 8 user's reference guide. Chicago: Scientific Software International, 1993.
31. Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis & Proteolysis 1996; 10 (suppl. 2): 171-179.
32. Walker ID. Blood collection and sample preparation: pre-analytic variation. In: Jespersen J, Bertina RM, Haverkate F, eds. Laboratory techniques in thrombosis. A manual. Second revised edition of the ECAT assay procedures. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1992: 21-28.
33. Ranby M, Sundell IB, Nilsson TK. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917-922.
34. Sobey WJ, Beer SF, Carrington CA et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989; 260: 535-541.
35. Ruige JB, Dekker JM, Nijpels G et al. Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucose. Diabetetologia 1999; 42: 177-180.
36. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
37. Kluft C, Meijer P, Ersdal E, Rosen S. Tissue-type plasminogen activator (t-PA) activity. In: Jespersen J, Bertina RM, Haverkate F (eds) Laboratory techniques in thrombosis. A Manual. Second revised edition of the ECAT assay procedures. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1992; 223-230.
38. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246.
39. Ranby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 1989; 61: 409-414.
40. Meijer P, Pollet DE, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem 1994; 40: 110-115.
41. McCullagh P, Nelder JA. Generalized linear models, 2nd edn. London: Chapman and Hall 1989; 61-70.
42. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 27: 409-437.
43. Cotlove E, Harris EK, Williams GZ. Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3. Physiological and medical implications. Clin Chem 1970; 16: 1028-1032.
44. Bland JM, Altman DG. Measuring agreement in method comparison studies. Statistical Methods in Medical Research 1999; 8: 135-160.
45. Salomaa V, Rasi V, Stengard J et al. Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up. Thromb Haemost 1998; 79: 969-974.
46. Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G, Shen YL . Short-term intraindividual variability in lipoprotein measurements: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1992; 136: 1069-1081.
47. Chambless LE, McMahon R. Wu K, Folsom A, Finch A, Shen YL. Short-term intraindividual variability in hemostatis factors. The ARIC Study. Ann Epidemiol 1992; 2: 723-733.
48. Wallnöfer AE, Van Griensven JMT, Schoemaker HC et al. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. Thromb Haemostas 1993; 70: 1005-1008.
49. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostasis study-IV. Intraindividual variability and reliability of hemostatic factors. The Atherosclerosis Risk in Communities (ARIC). Thromb Haemost 1995; 73: 256-260.